RSI: rapid sequence induction PRACTICAL RECOMMENDATIONS Clinicians should be aware of the potential perioperative risk in patients receiving GLP-1RAs, GIP/ GLP-1RA and SGLT2 inhibitors
This dual mechanism often produces even more pronounced appetite suppression and weight loss than semaglutide alone, but it also means more aggressive slowing of gastric emptying
PubMed CrossRef Richards JR, Dorand MF, Royal K, et al
Market-Sizing and Forecasting: A hybrid top-down and bottom-up model was constructed, reconstructing demand from prescription volume data, patient population estimates, and treatment penetration rates across indications
"With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need." According to Eli Lilly, adults in the Phase 3 trials all lost weight with orforglipron and on the highest dose of 36 mg of orforglipron, the trial participants lost about 27 pounds over the course of 72 weeks or about 12% of their body weight, which is meaningful but not quite as high as some injectables
